New technique for dynamic monitoring of liquid tumor Cytotoxicity

If you are currently measuring the killing potency of an immunotherapy targeting liquid cancer cells using traditional endpoint assays such as Cr51 release and LDH assays, you are missing key elements of tumor cytotoxicity. Cancer-killing effectors do not always kill the targets at a constant pace. Have you optimized the incubation time of the effector/target co-culture and collect the readout at the peak of each cytotoxicity reaction.

We are excited to share the latest application note for xCELLigence Real Time Cell Analysis: "Evaluating Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin." The application note explains the principle of measuring the cytotoxicity of liquid tumors such as lymphoma, leukemia or myeloma continuously, in real-time and with unprecedented details. Key benefits include:

• Radiation-free
• Substantially reduced workload - just add effectors to targets and you are all set
• Continuous in real-time
• Assay windows spanning minutes to days
• Low, physiologically relevant effector:target ratios

Read the latest paper!